Blog Category

Scientific

Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR)

, , ,

/

27 March 2023

Biophytis to Present Sarconeos’ (BIO101) Development as a Drug Candidate in Rare Neuromuscular Diseases at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

, , ,

/

20 March 2023

Positive results from the Phase 2-3 COVA study presented at the 21 st ERS 2023 Lung Science Conference

,

/

9 March 2023

Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19

, , ,

/

2 February 2023

DECEMBER 1st, 2022

,

/

1 December 2022

Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19

, , ,

/

3 November 2022

Top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101)

, , ,

/

7 September 2022

Biophytis presents preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease

,

/

16 June 2022

Biophytis presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022

, , ,

/

19 April 2022

Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19

,

/

15 September 2021

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

,

/

13 July 2021

Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021

,

/

1 July 2021